Stephen Kimani,
MD, MSc
No Rating Available?
0
out of
5
Patient Rating
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the
minimum.
Languages Spoken: English, Swahili (individual language)
Specialties
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) Educational Commission for Foreign Medical Graduates |
Academic Locations
Huntsman Cancer Hospital
801-585-0255
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Assistant Professor (Clinical) |
| Academic Divisions | Oncology |
| Board Certification | American Board of Internal Medicine (Internal Medicine) Educational Commission for Foreign Medical Graduates |
Education History
| Fellowship | University of North Carolina School of Medicine Hematology/Oncology Fellow, 2021 |
| Fellowship | Fogarty International Center, National Institutes of Health Global Oncology Postdoctoral Fellow, 2020 |
| Internship | Duke University School of Medicine Internal Medicine Intern, 2018 |
| Residency | Duke University School of Medicine Internal Medicine Resident, 2018 |
| Graduate Training | Duke University Global Health M.Sc., 2014 |
| Professional Medical | University of Nairobi Medicine M.B.Ch.B., 2010 |
| Undergraduate | University of Nairobi Human Anatomy B.Sc. (Hons), 2007 |
Selected Publications - Journal Articles
Journal Article
- Ellis GK, Manda A, Topazian H, Stanley CC, Seguin R, Minnick CE, Tewete B, Mtangwanika A, Chawinga M, Chiyoyola S, Chikasema M, Salima A, Kimani S, Kasonkanji E, Mithi V, Kaimila B, Painschab MS, Gopal S, Westmoreland KD (2020). Feasibility of upfront mobile money transfers for transportation reimbursement to promote retention among patients receiving lymphoma treatment in Malawi. (Epub ahead of print) Int Health.
- Kimani SM, Painschab MS, Horner MJ, Muchengeti M, Fedoriw Y, Shiels MS, Gopal S (2020). Epidemiology of haematological malignancies in people living with HIV. Lancet HIV, 7(9), e641-e651.
- Watt MH, Kimani SM, Skinner D, Meade CS (2015). "Nothing Is Free": A Qualitative Study of Sex Trading Among Methamphetamine Users in Cape Town, South Africa. Arch Sex Behav, 45(4), 923-33.
- Ramadhani HO, Bartlett JA, Thielman NM, Pence BW, Kimani SM, Maro VP, Mwako MS, Masaki LJ, Mmbando CE, Minja MG, Lirhunde ES, Miller WC (2016). The Effect of Switching to Second-Line Antiretroviral Therapy on the Risk of Opportunistic Infections Among Patients Infected With Human Immunodeficiency Virus in Northern Tanzania. Open Forum Infect Dis, 3(1), ofw018.
- Meade CS, Towe SL, Watt MH, Lion RR, Myers B, Skinner D, Kimani S, Pieterse D (2015). Addiction and treatment experiences among active methamphetamine users recruited from a township community in Cape Town, South Africa: A mixed-methods study. Drug Alcohol Depend, 152, 79-86.
- Meade CS, Towe SL, Watt MH, Hobkirk AL, Skinner D, Myers B, Kimani SM, Pieterse D (2014). HIV testing behaviors and attitudes among community recruited methamphetamine users in a South African township. AIDS Behav, 19(1), 186-91.
- Kimani SM, Watt MH, Merli MG, Skinner D, Myers B, Pieterse D, MacFarlane JC, Meade CS (2014). Respondent driven sampling is an effective method for engaging methamphetamine users in HIV prevention research in South Africa. Drug Alcohol Depend, 143, 134-40.
- Ramadhani HO, Bartlett JA, Thielman NM, Pence BW, Kimani SM, Maro VP, Mwako MS, Masaki LJ, Mmbando CE, Minja MG, Lirhunde ES, Miller WC (2014). Association of first-line and second-line antiretroviral therapy adherence. Open Forum Infect Dis, 1(2), ofu079.
- Watt MH, Meade CS, Kimani S, MacFarlane JC, Choi KW, Skinner D, Pieterse D, Kalichman SC, Sikkema KJ (2013). The impact of methamphetamine ("tik") on a peri-urban community in Cape Town, South Africa. Int J Drug Policy, 25(2), 219-25.